search
Back to results

Zinc, Chromium, Vitamin C, and Copper Combination Supplement for Prediabetes Progression (CHANGE)

Primary Purpose

PreDiabetes, Nutrition

Status
Recruiting
Phase
Not Applicable
Locations
Indonesia
Study Type
Interventional
Intervention
Zinc, Chromium, Vitamin C, and Copper Supplementation
Standard healthy lifestyle intervention
Placebo
Sponsored by
Indonesia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for PreDiabetes focused on measuring Zinc, Chromium, Copper, Vitamin C

Eligibility Criteria

35 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adults aged between 35-65 years old;
  • Being prediabetes as assessed by having fasting plasma glucose (FPG) level in the range of 100 mg/dL to 125 mg/dL; having 2-h values in the oral glucose tolerance (OGTT) level in the range of 140 mg/dL to 199 mg/dL;
  • The study subjects will be recruited from household communities connected to any health care facilities such as primary health center, private clinics or private GP/specialist on the national health care system;
  • The subjects are willing to sign informed consent;
  • The subjects are willing to stay commitment during the study, at least 1 year;
  • Having app-android mobile

Exclusion Criteria:

  • Pregnancy or lactation women;
  • Transgender on hormonal injection;
  • Bariatric surgery;
  • Consuming other pills supplementation containing zinc and/or chromium, copper, vitamin C in regular basis;
  • History of Inflammatory Bowel Disease (IBD), psychiatric disorders, chronic diseases (e.g., HIV, Cushing syndrome, CKD, acromegaly, hyperthyroidism, etc.);
  • Not healthy (current status of the severely malnourished, acute problem of any severe disease, history of impaired hepatic, renal failure, heart failure, cancer, other catastrophic diseases.
  • Currently using weight loss medication;
  • Consuming pharmacology agents that might interfere the intervention (such as metformin, methylprednisolone, methyltestosterone, diuretics, complementary medicines);
  • Subjects who are unable to read and understand the statements of consent form

Sites / Locations

  • Human Nutrition Research Center, Indonesian Medical Education Research Institute (HNRC-IMERI) Faculty of Medicine, Universitas IndonesiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Experimental Group

Control group

Arm Description

A combination of Zinc, Chromium, Vitamin C, and Copper (ZCC supplement) with standard healthy lifestyle intervention

Placebo with standard healthy lifestyle intervention

Outcomes

Primary Outcome Measures

Change of Fasting Blood Glucose (FBG)
To investigate the effect of ZCC supplementation with standard healthy lifestyle intervention in improving Fasting Blood Glucose compared to placebo with standard healthy lifestyle intervention
Change of Hemoglobin A1c (HbA1c)
To investigate the effect of ZCC supplementation with standard healthy lifestyle intervention in improving HbA1c compared to placebo with standard healthy lifestyle intervention
Change of 2 hour Oral Glucose Tolerance Test (2-hour OGTT)
To investigate the effect of ZCC supplementation with standard healthy lifestyle intervention in improving 2 hour OGTT compared to placebo with standard healthy lifestyle intervention
Change of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
To investigate the effect of ZCC supplementation with standard healthy lifestyle intervention in improving HOMA-IR compared to placebo with standard healthy lifestyle intervention
Delay Onset of Type 2 Diabetes Mellitus (T2DM) Progression
Total participants who develop T2DM during study intervention as assessed by blood glucose
Change the Risk of T2DM Progression
Total participants whose blood glucose returned to normal during study intervention as assessed by blood glucose

Secondary Outcome Measures

Change in Lipid Profile (will be assessed by High Density Lipoprotein (HDL) in mg/dL, Low Density Lipoprotein (LDL) in mg/dL, Triglyceride (TG) in mg/dL, and total cholesterol in mg/dL))
To investigate the effect of ZCC supplementation among prediabetes adults on lipid profile (HDL, LDL, TG and total cholesterol)
Change in Body Weight (kilogram)
To investigate the effect of ZCC supplementation among prediabetes adults on changing in body weight.
Change in Body Mass Index (BMI) (weight and height will be combined to report the BMI in kg/m^2)
To investigate the effect of ZCC supplementation among prediabetes adults on changing in BMI.
Change in Percentage of Fat Mass (using Body Impedance Analysis)
To investigate the effect of ZCC supplementation among prediabetes adults on changing in fat mass using Body Impedance Analysis.
Change in Dietary intake
To determine the differences in changes of dietary intake after receiving 12 months of ZCC or placebo supplementation with standard healthy lifestyle intervention.
The Difference of Zinc Level among prediabetes adults
To determine the difference of Zinc level in prediabetes adults.
The Difference of Chromium Level among prediabetes adults
To determine the difference of Chromium level in prediabetes adults.
Change in Physical Activity (assessed by IPAQ Questionnaire)
To determine the difference of physical activity in prediabetes adults using standardized questionnaire on control and intervention group. Moderate intensity activities have been established as between 3 and 6 METS (metabolic equivalent of task). One MET is the amount of energy used while sitting quietly. Physical activities will be rated using METs to indicate their intensity. Vigorous-intensity activity activities have been established as >6 METs. The higher the MET scores mean a better physical activity.
The assessment on the Safety of the ZCC Supplementation for the respondents
To investigate the safety of the ZCC supplementation among prediabetes adults on the kidney function, liver function, and complete peripheral blood to assess whether the supplements have the specific effects for the respondents' organ function.

Full Information

First Posted
June 1, 2020
Last Updated
August 20, 2021
Sponsor
Indonesia University
Collaborators
Blackmores Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04511468
Brief Title
Zinc, Chromium, Vitamin C, and Copper Combination Supplement for Prediabetes Progression
Acronym
CHANGE
Official Title
A Combination of Zinc, Chromium, Vitamin C, and Copper Supplement for Prediabetes Progression: Randomized Controlled-Trial in Jakarta
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Recruiting
Study Start Date
June 23, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
March 21, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indonesia University
Collaborators
Blackmores Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Currently, the incidence of diabetes mellitus is increasing worldwide. People with prediabetes have higher risk to develop diabetes mellitus type 2. Several studies have proven that Zinc and Chromium are minerals that contribute to decreasing the level of blood glucose and insulin resistance. In addition, vitamin C also contributes in decreasing Fasting Blood Glucose (FBG) and Hemoglobin A1c (HbA1c). However, the eficacy of a combined zinc, chromium, vitamin C, and copper (ZCC) in decreasing blood glucose in prediabetic people has never been performed. The primary objective of this study is to investigate the effect of a combination of ZCC supplementation with standard healthy lifestyle counseling in improving glucose profile [Fasting Blood Glucose (FBG), 2-hour Oral Glucose Tolerance Test (OGTT), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)] from prediabetes to normal or reducing the risk of progression from prediabetes to Type 2-Diabetes Mellitus (T2DM) compared to placebo with standard healthy lifestyle intervention.
Detailed Description
Diabetes is an important public health problem as the number of people with diabetes are increasing across the world and contributes to high mortality burden. Prediabetes is an intermediate stage between normal glucose tolerance and type 2 diabetes mellitus. Furthermore, people with prediabetes have higher risk to develop diabetes mellitus type 2. There are several objectives in this study, such as primary objective, secondary objectives, and exploratory objectives. Primary Objective: To investigate the effect of a combination of Zinc, Chromium, Vitamin C, and Copper supplementation (ZCC supplementation) with standard healthy lifestyle intervention in improving glucose profile [Fasting Blood Glucose (FBG), 2-hour Oral Glucose Tolerance Test (OGTT), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)]) from prediabetes to normal (reducing the proportion of prediabetes and increasing the proportion to become normal) or reducing the risk of progression from prediabetes to Type 2-Diabetes Mellitus (T2DM) compared to placebo with standard healthy lifestyle intervention. Secondary Objectives: To investigate the level of Zinc and Chromium among the prediabetes, the safety of the ZCC supplementation, and the effect of a combination of Zinc, Chromium, Vitamin C, and Copper supplementation (ZCC supplementation) among prediabetic adults compared to the placebo supplementation on: Lipid profile [Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), Triglyceride]; Hemoglobin A1c (HbA1c); Dietary intake and physical activity Body weight and composition (body weight, Body Mass Index (BMI), body fat). Exploratory Objectives: To determine cost effectiveness of intervention on prediabetic adults comparing two different intervention models To determine the quality of life of prediabetes adults receiving a combination of zinc, chromium, vitamin C, and copper supplementation. Level of hs-crp; TNF-alpha and Vitamin C will be assessed later if needed (optional) Study Design: This study is a double-blind, randomized, placebo-controlled trial in the community setting, with two arms of intervention involving a total of 670 people. Study Duration: This study is a two-year study with 1 year of intervention for each subject.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PreDiabetes, Nutrition
Keywords
Zinc, Chromium, Copper, Vitamin C

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
There will be two arms of intervention: Arm 1: A combination of Zinc, Chromium, Vitamin C, and Copper (ZCC supplement) with standard healthy lifestyle intervention. Arm 2: A combination of placebo with standard healthy lifestyle intervention.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Independent party will mask the product.
Allocation
Randomized
Enrollment
670 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental Group
Arm Type
Experimental
Arm Description
A combination of Zinc, Chromium, Vitamin C, and Copper (ZCC supplement) with standard healthy lifestyle intervention
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Placebo with standard healthy lifestyle intervention
Intervention Type
Dietary Supplement
Intervention Name(s)
Zinc, Chromium, Vitamin C, and Copper Supplementation
Intervention Description
Combination of mineral and vitamin supplementation that consist of Zinc, Chromium, Vitamin C, and Copper
Intervention Type
Behavioral
Intervention Name(s)
Standard healthy lifestyle intervention
Intervention Description
Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo with inactive ingredients
Primary Outcome Measure Information:
Title
Change of Fasting Blood Glucose (FBG)
Description
To investigate the effect of ZCC supplementation with standard healthy lifestyle intervention in improving Fasting Blood Glucose compared to placebo with standard healthy lifestyle intervention
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Title
Change of Hemoglobin A1c (HbA1c)
Description
To investigate the effect of ZCC supplementation with standard healthy lifestyle intervention in improving HbA1c compared to placebo with standard healthy lifestyle intervention
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Title
Change of 2 hour Oral Glucose Tolerance Test (2-hour OGTT)
Description
To investigate the effect of ZCC supplementation with standard healthy lifestyle intervention in improving 2 hour OGTT compared to placebo with standard healthy lifestyle intervention
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Title
Change of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Description
To investigate the effect of ZCC supplementation with standard healthy lifestyle intervention in improving HOMA-IR compared to placebo with standard healthy lifestyle intervention
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Title
Delay Onset of Type 2 Diabetes Mellitus (T2DM) Progression
Description
Total participants who develop T2DM during study intervention as assessed by blood glucose
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Title
Change the Risk of T2DM Progression
Description
Total participants whose blood glucose returned to normal during study intervention as assessed by blood glucose
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Secondary Outcome Measure Information:
Title
Change in Lipid Profile (will be assessed by High Density Lipoprotein (HDL) in mg/dL, Low Density Lipoprotein (LDL) in mg/dL, Triglyceride (TG) in mg/dL, and total cholesterol in mg/dL))
Description
To investigate the effect of ZCC supplementation among prediabetes adults on lipid profile (HDL, LDL, TG and total cholesterol)
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Title
Change in Body Weight (kilogram)
Description
To investigate the effect of ZCC supplementation among prediabetes adults on changing in body weight.
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Title
Change in Body Mass Index (BMI) (weight and height will be combined to report the BMI in kg/m^2)
Description
To investigate the effect of ZCC supplementation among prediabetes adults on changing in BMI.
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Title
Change in Percentage of Fat Mass (using Body Impedance Analysis)
Description
To investigate the effect of ZCC supplementation among prediabetes adults on changing in fat mass using Body Impedance Analysis.
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Title
Change in Dietary intake
Description
To determine the differences in changes of dietary intake after receiving 12 months of ZCC or placebo supplementation with standard healthy lifestyle intervention.
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Title
The Difference of Zinc Level among prediabetes adults
Description
To determine the difference of Zinc level in prediabetes adults.
Time Frame
Baseline (at the beginning of study)
Title
The Difference of Chromium Level among prediabetes adults
Description
To determine the difference of Chromium level in prediabetes adults.
Time Frame
Baseline (at the beginning of study)
Title
Change in Physical Activity (assessed by IPAQ Questionnaire)
Description
To determine the difference of physical activity in prediabetes adults using standardized questionnaire on control and intervention group. Moderate intensity activities have been established as between 3 and 6 METS (metabolic equivalent of task). One MET is the amount of energy used while sitting quietly. Physical activities will be rated using METs to indicate their intensity. Vigorous-intensity activity activities have been established as >6 METs. The higher the MET scores mean a better physical activity.
Time Frame
Baseline (at the beginning of study), Intervention Period (3 and 6 months), and 12 months
Title
The assessment on the Safety of the ZCC Supplementation for the respondents
Description
To investigate the safety of the ZCC supplementation among prediabetes adults on the kidney function, liver function, and complete peripheral blood to assess whether the supplements have the specific effects for the respondents' organ function.
Time Frame
Baseline (at the beginning of study) and 12 months (end of the study)
Other Pre-specified Outcome Measures:
Title
Cost Effectiveness Analysis of ZCC Supplement using Incremental cost-effectiveness ratio (ICER)
Description
Analyzing the cost effectiveness of intervention on Prediabetic adults comparing 2 different intervention models using incremental cost-effectiveness ratio (ICER). ICER is the ratio of the change in costs of a therapeutic intervention (compared to the alternative, such as doing nothing or using the best available alternative treatment) to the change in effects of the intervention.
Time Frame
through study completion, an average of 1 year
Title
Change of Quality of Life Questionnaire (assessed by SF-36 questionnaire)
Description
To determine the quality of life of prediabetes adults using standardized questionnaire on control and intervention group. he range of scores is between 15 to 105, with a higher score or number being indicative of a higher quality of life.
Time Frame
through study completion, an average of 1 year
Title
Change in High-sensitivity C-Reactive Protein (hs-CRP) level (optional)
Description
To determine the difference of hs-CRP level in prediabetes adults with ZCC and placebo supplementation (optional).
Time Frame
through study completion, an average of 2 year
Title
Change in Tumor Necrosis Factor-alpha (TNF-alpha) Level (optional)
Description
To determine the difference of TNF-alpha level in prediabetes adults with ZCC and placebo supplementation (optional).
Time Frame
through study completion, an average of 2 year
Title
Change in Vitamin C Level (optional)
Description
To determine the difference of Vitamin C level in prediabetes adults with ZCC and placebo supplementation (optional).
Time Frame
through study completion, an average of 2 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adults aged between 35-65 years old; Being prediabetes as assessed by having fasting plasma glucose (FPG) level in the range of 100 mg/dL to 125 mg/dL; having 2-h values in the oral glucose tolerance (OGTT) level in the range of 140 mg/dL to 199 mg/dL; The study subjects will be recruited from household communities connected to any health care facilities such as primary health center, private clinics or private GP/specialist on the national health care system; The subjects are willing to sign informed consent; The subjects are willing to stay commitment during the study, at least 1 year; Having app-android mobile Exclusion Criteria: Pregnancy or lactation women; Transgender on hormonal injection; Bariatric surgery; Consuming other pills supplementation containing zinc and/or chromium, copper, vitamin C in regular basis; History of Inflammatory Bowel Disease (IBD), psychiatric disorders, chronic diseases (e.g., HIV, Cushing syndrome, CKD, acromegaly, hyperthyroidism, etc.); Not healthy (current status of the severely malnourished, acute problem of any severe disease, history of impaired hepatic, renal failure, heart failure, cancer, other catastrophic diseases. Currently using weight loss medication; Consuming pharmacology agents that might interfere the intervention (such as metformin, methylprednisolone, methyltestosterone, diuretics, complementary medicines); Subjects who are unable to read and understand the statements of consent form
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rina Agustina, MD, MSc, PhD
Phone
+62 21 3912477
Email
r.agustina@ui.ac.id; dr.rinaagustina@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Hanifa Hanifa, Master
Phone
+62 21 3912477
Email
hnrc.imeri@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rina Agustina, MD, MSc, PhD
Organizational Affiliation
HNRC-IMERI, Faculty of Medicine Universitas Indonesia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Human Nutrition Research Center, Indonesian Medical Education Research Institute (HNRC-IMERI) Faculty of Medicine, Universitas Indonesia
City
Jakarta Pusat
State/Province
DKI Jakarta
ZIP/Postal Code
10430
Country
Indonesia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rina Agustina, PhD
Phone
+62-21-3912477
Email
r.agustina@ui.ac.id
First Name & Middle Initial & Last Name & Degree
Hanifa Hanifa, MBiomed
Phone
+62-21-3912477
Email
hnrc.imeri@gmail.com
First Name & Middle Initial & Last Name & Degree
Rina Agustina, MD, MSc, PhD
First Name & Middle Initial & Last Name & Degree
Erfi Prafiantini, MD, MKes
First Name & Middle Initial & Last Name & Degree
Hanifa Hanifa, MBiomed
First Name & Middle Initial & Last Name & Degree
Pradana Soewondo, MD, Prof
First Name & Middle Initial & Last Name & Degree
Anuraj H Shankar, DSc

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22630043
Citation
Jayawardena R, Ranasinghe P, Byrne NM, Soares MJ, Katulanda P, Hills AP. Prevalence and trends of the diabetes epidemic in South Asia: a systematic review and meta-analysis. BMC Public Health. 2012 May 25;12:380. doi: 10.1186/1471-2458-12-380.
Results Reference
background
PubMed Identifier
22515411
Citation
Jayawardena R, Ranasinghe P, Galappatthy P, Malkanthi R, Constantine G, Katulanda P. Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2012 Apr 19;4(1):13. doi: 10.1186/1758-5996-4-13.
Results Reference
background
PubMed Identifier
30940641
Citation
Dall TM, Yang W, Gillespie K, Mocarski M, Byrne E, Cintina I, Beronja K, Semilla AP, Iacobucci W, Hogan PF. The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes. Diabetes Care. 2019 Sep;42(9):1661-1668. doi: 10.2337/dc18-1226. Epub 2019 Apr 2.
Results Reference
background
PubMed Identifier
22580730
Citation
Janghorbani M, Amini M. Normal fasting plasma glucose and risk of prediabetes and type 2 diabetes: the Isfahan Diabetes Prevention Study. Rev Diabet Stud. 2011 Winter;8(4):490-8. doi: 10.1900/RDS.2011.8.490. Epub 2012 Feb 10.
Results Reference
background
PubMed Identifier
18772457
Citation
Aroda VR, Ratner R. Approach to the patient with prediabetes. J Clin Endocrinol Metab. 2008 Sep;93(9):3259-65. doi: 10.1210/jc.2008-1091.
Results Reference
background
PubMed Identifier
10181011
Citation
Kelly FJ. Use of antioxidants in the prevention and treatment of disease. J Int Fed Clin Chem. 1998 Mar;10(1):21-3.
Results Reference
background
PubMed Identifier
23137858
Citation
Capdor J, Foster M, Petocz P, Samman S. Zinc and glycemic control: a meta-analysis of randomised placebo controlled supplementation trials in humans. J Trace Elem Med Biol. 2013 Apr;27(2):137-42. doi: 10.1016/j.jtemb.2012.08.001. Epub 2012 Nov 6.
Results Reference
background
PubMed Identifier
29072815
Citation
Ranasinghe P, Wathurapatha WS, Galappatthy P, Katulanda P, Jayawardena R, Constantine GR. Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial. J Diabetes. 2018 May;10(5):386-397. doi: 10.1111/1753-0407.12621. Epub 2018 Jan 3.
Results Reference
background
PubMed Identifier
23289009
Citation
Guo CH, Wang CL. Effects of zinc supplementation on plasma copper/zinc ratios, oxidative stress, and immunological status in hemodialysis patients. Int J Med Sci. 2013;10(1):79-89. doi: 10.7150/ijms.5291. Epub 2012 Dec 22.
Results Reference
background
PubMed Identifier
29773176
Citation
Kim HN, Kim SH, Eun YM, Song SW. Effects of zinc, magnesium, and chromium supplementation on cardiometabolic risk in adults with metabolic syndrome: A double-blind, placebo-controlled randomised trial. J Trace Elem Med Biol. 2018 Jul;48:166-171. doi: 10.1016/j.jtemb.2018.03.022. Epub 2018 Mar 30.
Results Reference
background
PubMed Identifier
19076553
Citation
Bartlett HE, Eperjesi F. Nutritional supplementation for type 2 diabetes: a systematic review. Ophthalmic Physiol Opt. 2008 Nov;28(6):503-23. doi: 10.1111/j.1475-1313.2008.00595.x.
Results Reference
background
PubMed Identifier
23683609
Citation
Abdollahi M, Farshchi A, Nikfar S, Seyedifar M. Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials. J Pharm Pharm Sci. 2013;16(1):99-114. doi: 10.18433/j3g022.
Results Reference
background
PubMed Identifier
10393138
Citation
Will JC, Ford ES, Bowman BA. Serum vitamin C concentrations and diabetes: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr. 1999 Jul;70(1):49-52. doi: 10.1093/ajcn/70.1.49.
Results Reference
background
PubMed Identifier
8546437
Citation
Eriksson J, Kohvakka A. Magnesium and ascorbic acid supplementation in diabetes mellitus. Ann Nutr Metab. 1995;39(4):217-23. doi: 10.1159/000177865.
Results Reference
background
PubMed Identifier
28294172
Citation
Ashor AW, Werner AD, Lara J, Willis ND, Mathers JC, Siervo M. Effects of vitamin C supplementation on glycaemic control: a systematic review and meta-analysis of randomised controlled trials. Eur J Clin Nutr. 2017 Dec;71(12):1371-1380. doi: 10.1038/ejcn.2017.24. Epub 2017 Mar 15.
Results Reference
background
PubMed Identifier
27242121
Citation
Islam MR, Attia J, Ali L, McEvoy M, Selim S, Sibbritt D, Akhter A, Akter S, Peel R, Faruque O, Mona T, Lona H, Milton AH. Zinc supplementation for improving glucose handling in pre-diabetes: A double blind randomized placebo controlled pilot study. Diabetes Res Clin Pract. 2016 May;115:39-46. doi: 10.1016/j.diabres.2016.03.010. Epub 2016 Mar 19.
Results Reference
background
PubMed Identifier
21570271
Citation
Sharma S, Agrawal RP, Choudhary M, Jain S, Goyal S, Agarwal V. Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes. J Trace Elem Med Biol. 2011 Jul;25(3):149-53. doi: 10.1016/j.jtemb.2011.03.003. Epub 2011 May 12.
Results Reference
background
PubMed Identifier
26302914
Citation
Paiva AN, Lima JG, Medeiros AC, Figueiredo HA, Andrade RL, Ururahy MA, Rezende AA, Brandao-Neto J, Almeida Md. Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: A randomized clinical study. J Trace Elem Med Biol. 2015 Oct;32:66-72. doi: 10.1016/j.jtemb.2015.05.006. Epub 2015 May 28.
Results Reference
background
PubMed Identifier
31123789
Citation
Vistisen D, Kivimaki M, Perreault L, Hulman A, Witte DR, Brunner EJ, Tabak A, Jorgensen ME, Faerch K. Reversion from prediabetes to normoglycaemia and risk of cardiovascular disease and mortality: the Whitehall II cohort study. Diabetologia. 2019 Aug;62(8):1385-1390. doi: 10.1007/s00125-019-4895-0. Epub 2019 May 23.
Results Reference
background
PubMed Identifier
24082728
Citation
Khan MI, Siddique KU, Ashfaq F, Ali W, Reddy HD, Mishra A. Effect of high-dose zinc supplementation with oral hypoglycemic agents on glycemic control and inflammation in type-2 diabetic nephropathy patients. J Nat Sci Biol Med. 2013 Jul;4(2):336-40. doi: 10.4103/0976-9668.117002.
Results Reference
background

Learn more about this trial

Zinc, Chromium, Vitamin C, and Copper Combination Supplement for Prediabetes Progression

We'll reach out to this number within 24 hrs